In a recent study, researchers compared the efficacy of nivolumab with chemotherapy on clinical outcomes among patients with melanoma that progressed following ipilimumab therapy.
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
In a breakthrough clinical trial, researchers tested a genetically engineered version of the herpes simplex virus designed to combat melanoma by multiplying inside cancer cells and killing them.
